ATE353639T1 - In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb - Google Patents

In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb

Info

Publication number
ATE353639T1
ATE353639T1 AT01916022T AT01916022T ATE353639T1 AT E353639 T1 ATE353639 T1 AT E353639T1 AT 01916022 T AT01916022 T AT 01916022T AT 01916022 T AT01916022 T AT 01916022T AT E353639 T1 ATE353639 T1 AT E353639T1
Authority
AT
Austria
Prior art keywords
astaxanthin
man
animal
inhibit
activation
Prior art date
Application number
AT01916022T
Other languages
English (en)
Inventor
Tove Andersson
Sven Pettersson
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Application granted granted Critical
Publication of ATE353639T1 publication Critical patent/ATE353639T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01916022T 2000-03-27 2001-03-21 In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb ATE353639T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines

Publications (1)

Publication Number Publication Date
ATE353639T1 true ATE353639T1 (de) 2007-03-15

Family

ID=20279020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916022T ATE353639T1 (de) 2000-03-27 2001-03-21 In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb

Country Status (8)

Country Link
EP (1) EP1267857B1 (de)
JP (1) JP2003528139A (de)
AT (1) ATE353639T1 (de)
AU (1) AU2001242965A1 (de)
CA (1) CA2405479C (de)
DE (1) DE60126591D1 (de)
SE (1) SE0001071D0 (de)
WO (1) WO2001072296A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048202A2 (en) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Nf-kappab activating genes
WO2005074907A1 (ja) * 2004-02-04 2005-08-18 Fuji Chemical Industry Co., Ltd. 遺伝子発現調節剤
JP2006008714A (ja) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd マトリックスメタロプロテイナーゼ阻害剤
JP2006008718A (ja) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd シクロオキシゲナーゼ活性阻害剤
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155736A (ja) * 1991-12-10 1993-06-22 Nakano Seiyaku Kk 化粧料
JPH0799924A (ja) * 1993-09-30 1995-04-18 Nippon Suisan Kaisha Ltd アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
CA2210957A1 (en) * 1995-02-03 1996-08-08 Basf Aktiengesellschaft The use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JPH09143063A (ja) * 1995-11-22 1997-06-03 Kose Corp 外用に適する組成物
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
WO1998045241A2 (en) * 1997-04-04 1998-10-15 Henkel Corporation Lutein esters having high bioavailability
SE512531C2 (sv) * 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Also Published As

Publication number Publication date
JP2003528139A (ja) 2003-09-24
CA2405479C (en) 2010-11-16
CA2405479A1 (en) 2001-10-04
DE60126591D1 (de) 2007-03-29
EP1267857A1 (de) 2003-01-02
AU2001242965A1 (en) 2001-10-08
EP1267857B1 (de) 2007-02-14
SE0001071D0 (sv) 2000-03-27
WO2001072296A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
AR003463A1 (es) Una formulacion de liberacion controlada o de liberacion retardada; su utilizacion en la fabricacion de un medicamento y un procedimiento para su preparacion.
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
MY111791A (en) Aqueous gel retinoid dosage form.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
TR200100610T2 (tr) Asetil L-karnitin ve alfa-lipoik asit içeren antioksidant bileşim
SE9704870D0 (sv) New pharmaceutical formulation I
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
DK1167354T3 (da) Racemisk huperzin A
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
MXPA03000089A (es) Uso de inhibidores de cinasa de tirosina de proteina de egf-r para prevenir el fotoenvejecimiento de la piel humana.
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
WO1987000432A3 (en) Use of melatonin or related compounds for the treatment of psoriasis
BR0108405A (pt) Agente de ativação de célula
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties